Evidence map›Paper›PMID 28102836›Full record

ArticleNature protocols2017

Preparation, characterization, and in vitro dosimetry of dispersed, engineered nanomaterials.

Glen M DeLoid, Joel M Cohen, Georgios Pyrgiotakis, Philip Demokritou

Abstract read
In one paragraph

Article in Nature protocols, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 147 papers.

0numbers the graph read from it
0cells of the map it votes in
147citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

147 citing papers in PubMed.

  1. Review
  2. Article
  3. Navigating theNanoscale advances · 2026
    Review
  4. Article
  5. Article
  6. Application of the Comet Assay in Advanced In Vitro Models.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  7. Article
  8. Transcriptomic profile of TiOArchives of toxicology · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Flame-Made Doped Iron Oxide Nanoparticles as Tracers for Magnetic Particle Imaging.Chemistry of materials : a publication of the American Chemical Society · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. SiOScientific reports · 2025
    Article
  20. Article

87 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Glen M DeLoidCenter for Nanotechnology and Nanotoxicology, HSPH-NIEHS Nanosafety Research Center, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA.
Joel M CohenCenter for Nanotechnology and Nanotoxicology, HSPH-NIEHS Nanosafety Research Center, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA.
Georgios PyrgiotakisCenter for Nanotechnology and Nanotoxicology, HSPH-NIEHS Nanosafety Research Center, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA.
Philip DemokritouCenter for Nanotechnology and Nanotoxicology, HSPH-NIEHS Nanosafety Research Center, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA.

Funding

Engineered Nanomaterial Synthesis, Characterization and Method Development Center for Nano-safety ResearchU24ES026946 · NIEHS · HARVARD SCHOOL OF PUBLIC HEALTH · PI DEMOKRITOU, PHILIP · 2016 to 2020
$3.8M
NIEHS NIH HHS U24 ES026946
6 · The paper itself

Abstract

Evidence continues to grow of the importance of in vitro and in vivo dosimetry in the hazard assessment and ranking of engineered nanomaterials (ENMs). Accurate dose metrics are particularly important for in vitro cellular screening to assess the potential health risks or bioactivity of ENMs. To ensure meaningful and reproducible quantification of in vitro dose, with consistent measurement and reporting between laboratories, it is necessary to adopt standardized and integrated methodologies for (i) generation of stable ENM suspensions in cell culture media; (ii) colloidal characterization of suspended ENMs, particularly of properties that determine particle kinetics in an in vitro system (size distribution and formed agglomerate effective density); and (iii) robust numerical fate and transport modeling for accurate determination of the ENM dose delivered to cells over the course of the in vitro exposure. Here we present an integrated comprehensive protocol based on such a methodology for in vitro dosimetry, including detailed standardized procedures for each of these three critical aims. The entire protocol requires ∼6-12 h to complete.

Indexed as

AnimalsBiological TransportCell LineEngineeringHumansModels, BiologicalNanostructuresNanotechnology

Identifiers

PMID28102836
PMCPMC5857388

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.